Trial Profile

A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deleted

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Talimogene laherparepvec (Primary)
Indications Early breast cancer; Male breast cancer
Focus Adverse reactions

Most Recent Events

11 Aug 2023 Status changed from active, no longer recruiting to discontinued.
22 Sep 2022 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
22 Sep 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com